Emerald Mutual Fund Advisers Trust Decreases Holdings in Spyre Therapeutics, Inc. $SYRE

Emerald Mutual Fund Advisers Trust decreased its holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 6.4% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 308,212 shares of the company’s stock after selling 21,218 shares during the period. Emerald Mutual Fund Advisers Trust owned approximately 0.51% of Spyre Therapeutics worth $5,166,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. California State Teachers Retirement System lifted its stake in Spyre Therapeutics by 1.8% in the second quarter. California State Teachers Retirement System now owns 33,201 shares of the company’s stock worth $497,000 after purchasing an additional 603 shares during the last quarter. F m Investments LLC increased its holdings in shares of Spyre Therapeutics by 1.4% in the second quarter. F m Investments LLC now owns 52,546 shares of the company’s stock worth $787,000 after buying an additional 702 shares during the period. AlphaQuest LLC lifted its stake in shares of Spyre Therapeutics by 30.8% in the 2nd quarter. AlphaQuest LLC now owns 4,174 shares of the company’s stock valued at $62,000 after acquiring an additional 983 shares during the last quarter. Ameritas Investment Partners Inc. boosted its holdings in Spyre Therapeutics by 25.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,091 shares of the company’s stock valued at $76,000 after acquiring an additional 1,045 shares during the period. Finally, ProShare Advisors LLC boosted its holdings in Spyre Therapeutics by 9.7% during the 2nd quarter. ProShare Advisors LLC now owns 12,479 shares of the company’s stock valued at $187,000 after acquiring an additional 1,101 shares during the period. Institutional investors own 80.39% of the company’s stock.

Spyre Therapeutics Trading Up 0.3%

Shares of Spyre Therapeutics stock opened at $34.09 on Friday. Spyre Therapeutics, Inc. has a 12-month low of $10.91 and a 12-month high of $35.31. The company has a market cap of $2.65 billion, a P/E ratio of -15.57 and a beta of 3.17. The company’s fifty day simple moving average is $31.23 and its two-hundred day simple moving average is $22.66.

Spyre Therapeutics (NASDAQ:SYRE) last announced its earnings results on Tuesday, November 4th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.53. Analysts predict that Spyre Therapeutics, Inc. will post -4.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SYRE has been the topic of a number of analyst reports. Wall Street Zen raised Spyre Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Spyre Therapeutics in a research note on Monday, December 29th. Jones Trading raised shares of Spyre Therapeutics from a “hold” rating to a “buy” rating and set a $64.00 price target for the company in a research report on Monday, December 1st. BTIG Research restated a “buy” rating and issued a $70.00 price objective on shares of Spyre Therapeutics in a research report on Friday, January 16th. Finally, Mizuho upgraded shares of Spyre Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Three analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Spyre Therapeutics presently has an average rating of “Buy” and an average price target of $53.88.

Insiders Place Their Bets

In other Spyre Therapeutics news, CEO Cameron Turtle sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $30.68, for a total transaction of $460,200.00. Following the transaction, the chief executive officer owned 671,907 shares in the company, valued at approximately $20,614,106.76. This represents a 2.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders sold 75,000 shares of company stock worth $1,945,350. Insiders own 15.43% of the company’s stock.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.